降低前列腺癌死亡率：雄激素剥夺假说的无支持推测。
Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.
机构信息
James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
出版信息
Eur Urol. 2014 Dec;66(6):973-4. doi: 10.1016/j.eururo.2014.06.051. Epub 2014 Jul 10.
PMID:25018035
Abstract
The reduction in prostate cancer deaths in the European Randomized Study of Screening for Prostate Cancer is best explained by a stage migration in the intervention arm, resulting in earlier effective treatment of localized prostate cancer compared with controls.
摘要
欧洲前列腺癌筛查随机研究中前列腺癌死亡率的降低，最好可以用干预组的分期转移来解释，与对照组相比，干预组中局限性前列腺癌的治疗更为有效，因此更早发现了肿瘤。
相似文献
1
Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.降低前列腺癌死亡率：雄激素剥夺假说的无支持推测。
Eur Urol. 2014 Dec;66(6):973-4. doi: 10.1016/j.eururo.2014.06.051. Epub 2014 Jul 10.
2
RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.主题：前列腺特异性抗原筛查试验与前列腺癌死亡：雄激素剥夺关联
J Natl Cancer Inst. 2014 Apr 26;106(5):dju079. doi: 10.1093/jnci/dju079.
3
Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.关于：前列腺特异性抗原筛查试验与前列腺癌死亡：雄激素剥夺的关联。
J Natl Cancer Inst. 2014 Feb;106(2):djt432. doi: 10.1093/jnci/djt432. Epub 2014 Jan 7.
4
Prostate cancer screening: biases and the need for consensus.前列腺癌筛查：偏差与达成共识的必要性。
J Natl Cancer Inst. 2013 Oct 16;105(20):1522-4. doi: 10.1093/jnci/djt266. Epub 2013 Oct 3.
5
Response.回应
J Natl Cancer Inst. 2014 Feb;106(2):djt433. doi: 10.1093/jnci/djt433. Epub 2014 Jan 7.
6
Response.回应
J Natl Cancer Inst. 2014 Apr 26;106(5):dju081. doi: 10.1093/jnci/dju081.
7
Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.前列腺特异性抗原筛查试验与前列腺癌死亡：雄激素剥夺的关联。
J Natl Cancer Inst. 2013 Oct 16;105(20):1534-9. doi: 10.1093/jnci/djt248. Epub 2013 Oct 3.
8
Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?试验组间治疗差异能否解释前列腺癌筛查的欧洲随机研究中前列腺癌死亡率的降低？
Eur Urol. 2019 Jun;75(6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. Epub 2019 Mar 28.
9
[Surgical and medical treatment for localized prostate cancer].[局限性前列腺癌的手术及药物治疗]
Gan To Kagaku Ryoho. 2007 Jul;34(7):1002-5.
10
The prostate cancer conundrum.前列腺癌难题
J Natl Cancer Inst. 2003 Jul 2;95(13):930-1. doi: 10.1093/jnci/95.13.930.
引用本文的文献
1
Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?试验组间治疗差异能否解释前列腺癌筛查的欧洲随机研究中前列腺癌死亡率的降低？
Eur Urol. 2019 Jun;75(6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. Epub 2019 Mar 28.
2
Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.糖原合酶激酶-3：前列腺癌治疗的潜在预防靶点。
Urol Oncol. 2015 Nov;33(11):456-63. doi: 10.1016/j.urolonc.2015.05.006. Epub 2015 Jun 4.
Zotero 插件